{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":24,"n_cols":5,"rows_kept":24,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[18,2,18,3],[19,2,19,3],[21,2,21,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910999696203321"]
[null,null,"Titolo",null,"RNA-Based Cancer Therapeutics : Techniques, Applications and Challenges in Prognosis / / edited by Narendra Kumar Sharma, Tikam Chand Dakal, Pawan Kumar Maurya, Gulshan Wadhwa"]
[null,null,"Pubbl/distr/stampa",null,"Singapore : , : Springer Nature Singapore : , : Imprint : Springer, , 2025"]
[null,null,"ISBN",null,"981-9634-56-3"]
[null,null,"Edizione",null,"[1st ed. 2025.]"]
[null,null,"Descrizione fisica",null,"1 online resource (XIII, 297 p. 26 illus., 24 illus. in color.)"]
[null,null,"Disciplina",null,"572.88"]
[null,null,"Soggetti",null,"RNA interference"]
[{"$nulls":4},"Cancer - Genetic aspects"]
[{"$nulls":4},"Medical genetics"]
[{"$nulls":4},"Cancer - Treatment"]
[{"$nulls":4},"Cancer"]
[{"$nulls":4},"Oncology"]
[{"$nulls":4},"RNA Interference"]
[{"$nulls":4},"Cancer Genetics and Genomics"]
[{"$nulls":4},"Clinical Genetics"]
[{"$nulls":4},"Cancer Therapy"]
[{"$nulls":4},"Cancer Biology"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Chapter 1. An Introduction to RNA-based Therapeutics -- Chapter 2. Application Of Advance Crispr/Cas-9 And Other Genomic Tools In RNA Based Therapeutics -- Chapter 3. Applications of Advance ASOs, RNA Mimics and Others in RNA-based Therapeutics -- Chapter 4. Global changes in genome and proteome by mi-RNAs in cancers and other diseases -- Chapter 5. Short- and long-non-coding RNA causes global alterations in the genome and proteome in cancer and other disorders -- Chapter 6. Predictive and Prognostic Relevance of miRNAs in Cancers and Other Diseases -- Chapter 7. Diagnostic, Prognostic, and Predictive Short and Long Non-coding RNA Biomarkers in Cancer -- Chapter 8. RNA-Based Molecular Applications as Tool Compounds in Diagnostic and Clinical Settings -- Chapter 9. Clinical trials on RNA-based therapeutics for the treatment of infectious diseases and other pathologies -- Chapter 10. Challenges and Opportunities Used in RNA-"]
[{"$nulls":4},"based Therapeutics -- Chapter 11. Pragmatic Clinical Methods, Tools and Amplification techniques used in RNA-based diagnostic applications -- Chapter 12. Practical Clinical Approaches Used in RNA-based Therapeutics."]
[null,null,null,"Sommario/riassunto","By consistently dedicating efforts to multi-omic and other high-throughput technologies, it is expected that RNA therapies will have a vital role in future personalized medicine approaches for cancer therapy. Within this framework, analyzing the genetic sequence of a patient's tumor would allow for the detection of crucial driver mutations or changes that cause resistance to drugs. These mutations may then be targeted with RNA therapies that are particularly designed to treat those particular variations. Recent clinical trials have shown that RNA-based therapies hold great potential for treating several illnesses. However, further investigations are required to improve the delivery materials and understand the RNA alterations linked to these groundbreaking drugs, in order to facilitate their integration into clinical practice. Ideally, these therapeutic substances would be specifically administered to the tumor cells of interest using a targeted delivery agent. In this hypothetical situation, the choice of medications for cancer patients would differ depending on the precise abnormalities detected in each person, potentially including inhibitors that target circuits known to cause resistance to treatments. However, doing a more thorough assessment of the challenges and potential benefits discussed in each chapter would enhance the capacity to critically analyze this rapidly evolving field of therapies. This book largely examines the latest developments and clinical studies related to RNA-based medications, while also examining the challenges and future possibilities linked with them. This method shows potential for greatly improving the prognosis of cancer patients."]